Next-best content surfaced to the rep, the same day.
An HCP engaging with clinical content is a high-intent signal. Appice scores the interest and surfaces the next-best approved asset — to the rep, the portal and email — before the interest cools.
Content opens, prescribing shifts, adherence gaps and adverse-event mentions — decided and executed before the moment is gone.
Production-grade · FDA / EMA / MLR / pharmacovigilance-aware · sub-200ms decisions at enterprise scale
The CRM shows the HCP engaged — but the follow-up still arrives days later, through the wrong channel, and patient drop-off is caught only at the refill gap.
Signal detected. Decision made. Action taken — before the moment closes. Tap any card to zoom in. Scroll for more.
An HCP engaging with clinical content is a high-intent signal. Appice scores the interest and surfaces the next-best approved asset — to the rep, the portal and email — before the interest cools.
An adverse-event keyword in a patient app, call or portal interaction is detected, classified for severity, and routed to pharmacovigilance intake within minutes — never lost in a batch queue.
A missed dose or refill-gap signal triggers a tailored adherence intervention — reminder, nurse-educator call, or hub outreach — chosen by the patient’s risk and consent state.
A shift in prescribing or a clinical-content deep-dive flags a scientific-exchange opportunity. The MSL is queued with full context — within promotional / non-promotional firewall rules.
When a payer adds the product to formulary, the affected HCPs and field team are activated the same day — with the access change, patient-eligibility detail and approved messaging.
Enrolment into a patient support program triggers a personalised onboarding journey — welcome, benefits verification, injection training and copay support — sequenced to the patient’s therapy start.
A sample request is checked against eligibility, state licence and sample-accountability limits, fulfilled, and logged — automatically, with the rep notified for the follow-up conversation.
Congress booth visits, session attendance and content scans become real-time signals — each HCP gets a follow-up tailored to what they actually engaged with, while the conversation is fresh.
An HCP exploring efficacy, dosing or access pages signals an open question. Appice surfaces the next-best approved asset in-session and routes a rep or MSL follow-up if the depth warrants it.
A claim rejection, prior-authorisation delay or copay-shock signal triggers hub services — copay assistance, PA support or a bridge program — before cost stalls the start of therapy.
HCP Signal → Next-Best Content
Content open, portal visit or congress scan → the next-best approved asset routed to the right channel.
Adverse Event → PV Routing
AE mention detected, classified and routed to pharmacovigilance intake within the reporting window.
Refill Gap → Adherence Save
Missed dose or refill gap → the right adherence intervention before it becomes a discontinuation.
Access Win → Field Activation
Formulary change → affected HCPs and the field team activated the day access opens, with approved messaging.
Inbound Enquiry → Best Next Action
Call, portal, email or medical-information request → full context and the right action inside the agent desktop.
Congress & Portal → Scientific Follow-up
Booth, session and digital engagement → same-day rep or MSL follow-up tailored to what the HCP explored.
Appice plugs into Veeva, Salesforce Health Cloud, IQVIA OCE and major pharma CRM, master-data and content (PromoMats / Vault) systems — plus patient-support-program hubs, contact centres and pharmacovigilance intake. We don't replace your stack; we add the real-time decisioning layer across HCP and patient journeys.
Your data stays inside your governance. On-premise, private cloud or hybrid — with regulator-ready audit trails per decision.
Compliance is not bolted on. Every Appice decision in life sciences carries consent checks, MLR-state checks, reason codes and a full audit trail — ready for medical, regulatory and pharmacovigilance review at any time.
Consent → Enforced
Every HCP and patient comm checked against live preference centre & channel-suppression rules before it fires.
Content → MLR-Approved
Only assets in an approved MLR state can be sent — expiry and version controlled, per market.
AI → Explainable
Every Allyvate recommendation includes a human-readable reason code. No black box for HCP or patient decisions.
Data → Sovereign
Residency, region failover and model governance built in — on-prem or your cloud.
A global pharmaceutical company with a multi-therapy portfolio, a field force of several thousand reps and MSLs, and patient-support programs across specialty brands. HCP engagement ran on batch CRM campaigns; patient adherence outreach was generic and calendar-scheduled.
HCP follow-up was disconnected from real engagement signals — content opens, portal visits and congress activity sat in reports nobody acted on in time. Patient adherence outreach was calendar-based, not risk-based. Adverse-event mentions in patient channels were caught only in batch review.
Sense connected the CRM, content platform, patient-support-program hub, web portal and congress signals. Decide modelled HCP intent, prescribing shifts, patient adherence risk and adverse-event severity. Allyvate AI generated next-best content, adherence and field-activation journeys with MLR and consent vetting per market. Act executed across rep CRM, email, portal, hub and the medical desktop in lock-step.
2.3× HCP content engagement. 31% improvement in patient adherence on specialty brands. 38% faster adverse-event intake. HCP and patient engagement moved from batch campaigns to a real-time, agentic, audit-ready operating model — with measurable commercial and clinical outcomes.